Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on
View HTML
Toggle Summary Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
Rolling NDA submission for zuranolone in MDD underway, with full submission expected to be completed in the second half of 2022, associated NDA submission in PPD planned for early 2023 Topline data from Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD on track for mid-2022 Six planned and
View HTML
Toggle Summary Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
The companies expect to complete submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression anticipated in the first half of 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc.
View HTML
Toggle Summary Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 19, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 3, 2022 at 8:00 a.m.
View HTML
Toggle Summary Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
Data to be Presented During the Emerging Science Session at the American Academy of Neurology’s 74th Annual Meeting The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild
View HTML
Toggle Summary Sage Therapeutics to Present at 2022 Stifel CNS Days
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at
View HTML
Toggle Summary Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
Data Presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders The PARADIGM Study is a Phase 2, open-label study evaluating the safety, tolerability, and efficacy of SAGE-718 once daily in
View HTML
Toggle Summary Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will
View HTML
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
Rolling NDA submission for zuranolone in MDD expected to begin in early 2022 and planned to be completed in the second half of 2022 now supported by data from six positive clinical studies An associated NDA submission in PPD expected in 2023; Fast Track designation received for zuranolone in PPD
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms Key secondary endpoint demonstrates zuranolone co-initiated with an antidepressant was statistically significant in reducing
View HTML